Therapeutic developments in amyotrophic lateral sclerosis

Bibliography

• CHARCOT JM: De la sclerose laterale amyotrophique: symptomatologie. Prog. Med. (1874) 29:453–455.
   Google Scholar
• TANDAN R, BRADLEY WG: Amyotrophic lateral sclero-sis: Part 1. Clinical features, pathology, and ethical is-sues in management. Ann. Neurol. (1985) 18:271–280.
   PubMed Web of Science ®Google Scholar
• MUNSAT TL, ANDRES PL, FINISON L, CONLON T, THI-BODEAU L: The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology (1988) 38:409–413.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DB, WINDEBANK AJ: Motor neuron disease(amyotrophic lateral sclerosis). Mayo Clin. Proc. (1991) 66:54–82.
   PubMed Web of Science ®Google Scholar
• NORRIS F, SHEPHARD R, DENYS E et al.: Onset, natural history and outcome in idiopathic adult motor neuron disease. J. Neurol. Sci. (1993) 118:48–55.
   PubMed Web of Science ®Google Scholar
• RINGEL SP, MURPHY JR, ALDERSON MK et al.: The natural history of amyotrophic lateral sclerosis. Neurology (1993) 43:1316–1322.
   PubMed Web of Science ®Google Scholar
• ROWLAND LP: Amyotrophic lateral sclerosis. Curr. Opin. Neurol. (1994) 7:310–315.
   PubMed Web of Science ®Google Scholar
• KURTZKE JF, BEEBE GW: Epidemiology of amyotrophic lateral sclerosis: 1. A case-control comparison based on ALS deaths. Neurology (1980) 30:453–462.
   Google Scholar
• JUERGENS SM, KURLAND LT, OKAZAKI H, MULDER DW: ALS in Rochester, Minnesota, 1925-1977. Neurology (1980) 30:463–470.
   PubMed Web of Science ®Google Scholar
• MITSUMOTO H, HANSON MR, CHAD DA: Amyotrophic lateral sclerosis: recent advances in pathogenesis and therapeutic trials. Arch. Neurology (1988) 45:189–202.
   PubMed Web of Science ®Google Scholar
• ANNEGERS JF, APPEL S, LEE J R-J, PERKINS P: Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch. Neurol. (1991) 48:589–593.
   PubMed Web of Science ®Google Scholar
• HAVERKAMP LJ, APPEL V, APPEL SH: Natural history ofamytrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain (1995) 118:707–719.
   PubMed Web of Science ®Google Scholar
• SUBCOMMITTEE ON MOTOR NEURON DISEASE/AMYO-TROPHIC LATERAL SCLEROSIS OF THE WORLD FEDERA-TION OF NEUROLOGY RESEARCH GROUP ON NEUROMUSCULAR DISEASE AND THE EL ESCORIAL 'CLINICAL LIMITS OF AMYOTROPHIC LATERAL SCLERO-SIS' WORKSHOP CONTRIBUTORS: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. (1994) 124 (Suppl.):96–107.
   Google Scholar
• BROWNELL B, OPPENHEIMER DR, HUGHES JT: The cen-tral nervous system in motor neuron disease. J. Neurol. Neurosurg. PsychiaL (1970) 33:338–357.
   PubMed Web of Science ®Google Scholar
• LOWE J, LENNOX G, LEIGH P: Disorders of movementand systems degenerations. In: Greenfields Neuropathol-ogy (6th ed). Graham D, Lantos P (Eds.), Arnold, London, UK (1997):281–366.
   Google Scholar
• HANSEN S, BALLANTYNE JP: A quantitative electro-physiological study of motor neurone disease. J. Neu-rol. Neurosurg. PsychiaL (1978) 41:773–783.
   PubMed Web of Science ®Google Scholar
• HUGHES JT: Pathology of amyotrophic lateral sclero-sis. Adv. Neurol. (1982) 36:61–73.
   PubMedGoogle Scholar
• MANNEN T, IWATA M, TOYOKURA Y, NAGASHIMA KJ:Preservation of a certain motoneurone group of the sacral cord in amyotrophic lateral sclerosis: its clinical significance. J. Neurol. Neurosurg. PsychiaL (1977) 40:464–469.
   PubMed Web of Science ®Google Scholar
• HIRANO A: Cytopathology in amyotrophic lateral scle-rosis. Adv. Neurol. (1991) 56:91–101.
   PubMedGoogle Scholar
• SIDDIQUE TS, FIGELWICZ DA, PERICAK-VANCE MA et al.:Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. New Engl. J. Med. (1991) 324:1381–1384.
   PubMed Web of Science ®Google Scholar
• ROSEN A, SIDDIQUE TS, PATTERSON DA etal.: Mutationsin Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59–62.
   Google Scholar
• SIDDIQUE T, DENG HX: Genetics of amyotrophic lat-eral sclerosis. Hum. Mol. Genet. (1996) 5:1465–1470.
   PubMed Web of Science ®Google Scholar
• RADUNOVIC A, LEIGH PN: Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: cor-relation between genotype and clinical features. J. Neu-rol. Neurosurg. PsychiaL (1996) 61:565–572.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ ME, MCKENNA-YASEK D, SAPP PE et al.:Epidemiology of mutations in superoxide dismutase in amyotrophic lateral scleroisi. Ann. Neurol. (1997) 41:210–221.
   PubMed Web of Science ®Google Scholar
• AL-CHALABI A, ANDERSEN PM, CHIOZA B et al.: Reces-sive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evi-dence for a linked protective factor. Hum. Mol. Genet. (1998) 7:2045–2050.
   PubMed Web of Science ®Google Scholar
• HENTATI A, BEJAOUI K, PERICAK-VANCE MA et al.: Link-age of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-35. Nature Genet. (1994) 7:425–428.
   PubMed Web of Science ®Google Scholar
• TANDAN R, BRADLEY WG: Amyotrophic lateral sclero-sis: Part 2. Etiopathogenesis. Ann. Neurol. (1985) 18:419–431.
   PubMed Web of Science ®Google Scholar
• APPEL SH, STEFANI E: Amyotrophic lateral sclerosis:etiology and pathogenesis. Curr. Neurol. (1991) 11:287–310.
   Google Scholar
• ROWLAND LP: Amyotrophic lateral sclerosis: humanchallenge for neuroscience. Proc. Nati Acad. Sci. USA (1995) 92:1251–1253.
   PubMed Web of Science ®Google Scholar
• BROWN RH: Amyotrophic lateral sclerosis: insightsfrom genetics. Arch. Neurol. (1997) 54:1246–1250.
   PubMed Web of Science ®Google Scholar
• AL-CHALABI A, ANDERSON PM, NILSSON P et al.: Deletions of the heavy neurofilament subunit tail in amyo-trophic lateral sclerosis. Hum. Mol. Genet. (1999) 8:157–164.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD: Excitotoxicity hypothesis. Neurology(1996) 47 (Supp1.2):S19–S26.
   Google Scholar
• BROWN RH: Superoxide dismutase and oxidative stress in amyotrophic lateral sclerosis. In: Oxidative Stress and the Molecular Biology of Anti-oxidant Defenses. Laboratory Press, Cold Spring Harbor, USA (1996):569–586.
   Google Scholar
• SMITH RG, SIKLOS L, ALEXIANU ME et al.: Autoimmunity and ALS. Neurology (1996) 47 (Suppl. 2) :S40–S46.
   Google Scholar
• COTE F, COLLARD JF, JULIEN JP: Progressive neurono-pathy in transgenic mice expressing the human neu-rofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell (1993) 73:35–46.
   PubMed Web of Science ®Google Scholar
• FIGLEWICZ DA, KRIZUS A, MARTINOLI MG etal.: Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclero-sis. Hum. Mol. Genet. (1994) 3:1757–1761.
   Google Scholar
• SMITH RA, MELMED S, SHERMAN B, FRANE J, MUNSAT TL, FESTOFF BW: Recombinant growth hormone treat-ment of amyotrophic lateral sclerosis. Muscle Nerve (1993) 16:624–633.
   PubMed Web of Science ®Google Scholar
• APPEL SH, STEWART SS, APPEL V et al.: A double-blind study of the effectiveness of cyclosporine in amyo-trophic lateral sclerosis. Arch. Neurol. (1987) 45:381–386.
   Web of Science ®Google Scholar
• JOSSAN SS, EKBLOM J, GUDJONSSON 0, HAGBARTH KE, AQUILONIUS SM: Double blind cross over trial with de-prenyl in amyotrophic lateral sclerosis. J. Neural. Transmiss. Supp. (1994) 41:237–241.
   PubMedGoogle Scholar
• DALAKAS MC, STEIN DP, OTERI C, SEKUL E, CUPLER EJ, MCCROSKY S: Effect of high-dose intravenous immu-noglobulin on amyotrophic lateral sclerosis and mul-tifocal motor neuropathy. Arch. Neurol. (1994) 51:861–864.
   PubMed Web of Science ®Google Scholar
• DRACHMAN DB, CHAUDHRY V, CORNBLATH D et al.: Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Neurol. (1994) 35:142–150.
   PubMed Web of Science ®Google Scholar
• EISEN A, STEWART H, SCHULZER M, CAMERON D: Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can. J. Neurol Sci. (1993) 20:297–301.
   PubMed Web of Science ®Google Scholar
• NORRIS FH, TAN Y, FALLAT RJ, ELIAS L: Trial of oral phy-sostigmine in amyotrophic lateral sclerosis. Clin. Pharm. Ther. (1993) 54:680–682.
   PubMed Web of Science ®Google Scholar
• WESTARP ME, BARTMANN P, ROSSLER J et al.: Antiretro-viral therapy in sporadic adult amyotrophic lateral sclerosis. NeuroReport (1993) 4:819–822.
   PubMed Web of Science ®Google Scholar
• ASKMARK H, AQUILONIUS SM, GILLBERG PG, LIEDHOLM LJ, STALBERG E, WUOPIO R: A pilot trial of dex-tromethorphan in amyotrophic lateral sclerosis. J. Neurol Neurosurg. Psychiat. (1993) 56:197–200.
   PubMed Web of Science ®Google Scholar
• TESTA D, CARACENI T, FETONI V, GIROTTI F: Chronictreatment with L-threonine in amyotrophic lateral
   Google Scholar
• sclerosis: a pilot study. Clin. Neurol Neurosurg. (1992) 4:7–9.
   Google Scholar
• TESTA D, CHIODINI PG, GIROTTI F, ATTANASIO R: Amyotrophic lateral sclerosis: thyroid and prolactin hormone changes in thyrotropin-releasing hormone therapy. Ital. j Neurol. Sci. (1990) 11:601–603.
   PubMedGoogle Scholar
• ASKMARK H, AQUILONIUS SM, GILLBERG PG et al.: Func-tional and pharmacokinetic studies of tetrahydroami-noacridine in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. (1990) 82:253–258.
   PubMedGoogle Scholar
• MILLER SC, WARNICK JE: Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. The role of androgens. Arch. Neurol (1989) 46:330–335.
   PubMed Web of Science ®Google Scholar
• BROOKS BR: A summary of the current position of TRH in ALS therapy. Ann. New York Acad. Sci. (1989) 553:431–461.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, BOUCHE P, BENSIMON G, MEUBUBGER V: A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology (1989) 39:1635–1637.
   PubMed Web of Science ®Google Scholar
• TESTA D, CARACENI T, FETONI V: Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J. Neurol (1989) 236:445–447.
   PubMed Web of Science ®Google Scholar
• MORA JS, MUNSAT TL, KAO KP: eta].: Intrathecal admini-stration of natural human interferon alpha in amyo-trophic lateral sclerosis. Neurology (1986) 36:1137–1140.
   Google Scholar
• DALAKAS MC, AKSAMIT AJ, MADDEN DL, SEVER JL: Ad-ministration of recombinant human leukocyte alpha 2-interferon in patients with amyotrophic lateral scle-rosis. Arch. Neurol (1986) 43:933–935.
   PubMed Web of Science ®Google Scholar
• OLARTE MR, SHAFER SQ: Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis. Neurology (1985) 35:1063–1066.
   PubMed Web of Science ®Google Scholar
• JONES TM, YU R, ANTEL JP: Response of patients with amyotrophic lateral sclerosis to testosterone therapy: endocrine evaluation. Arch. Neurology (1982) 39:721–722.
   PubMed Web of Science ®Google Scholar
• SILANI V, SCARLATO G, VALLI G, MARCONI M: Plasma ex-change ineffective in amyotrophic lateral sclerosis. Arch. Neurol. (1980) 37:511–513.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD: Therapeutic horizons for amyotrophic lateral sclerosis. Curr. Opin. Neurobiol. (1996) 6:679–687.
   PubMed Web of Science ®Google Scholar
• MILLER RG, SUFIT R: New approaches to the treatment of ALS. Neurology (1997) 48 (Supp1.4):528–532.
   Google Scholar
• LOUVEL E, HUGON J, DOBLE A: Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharm. Sci. (1997) 18:196–203.
   PubMed Web of Science ®Google Scholar
• MITSUMOTO H: New therapeutic approaches: rationale and results. In: Motor Neuron Disease. Leigh PN, Swash M (Eds.), Springer, London, UK (1995) :419–441.
   Google Scholar
• FESTOFF BW: Amyotrophic lateral sclerosis: current and future treatment strategies. Drug (1996) 51:28–44.
   PubMed Web of Science ®Google Scholar
• CHOI DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 1:623–634.
   PubMed Web of Science ®Google Scholar
• LEIGH PN, MELDRUM BS: Excitotoxicity in ALS. Neurol-ogy (1996) 47 (Supp1.4):S221–S227.
   Google Scholar
• PLAITAKIS A: Glutamate dysfunction and selective mo-tor neuron degeneration in amyotrophic lateral scle-rosis: a hypothesis. Ann. Neurology (1990) 28:3–8.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, MARTIN LJ, KUNCL RW: Decreased gluta-mate transport by the brain and spinal cord in amyo-trophic lateral sclerosis. New EngL J. Med. (1992) 326:1464–1468.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, VAN KAMMEN M, LEVEY Al, MARTIN L, KUNCL RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. (1995) 38:73–84.
   PubMed Web of Science ®Google Scholar
• LIN CL, BRISTOL LA, JIN L et al.: Aberrant RNA processing in a neurodegenerative disease: the cause of absent EAAT2, a glutamate transporter, in amyotrophic lat-eral sclerosis. Neuron (1998) 20:589–602.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, JIN L, DYKES-HOBERG M, KUNCL RW: Chronic glutamate uptake inhibition produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA (1993) 90:6591–6595.
   PubMed Web of Science ®Google Scholar
• BOWLING AC, SCHULZ JB, BROWN RHJ, BEAL MF: Super-oxide dismutase activity, oxidative damage and mito-chondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. (1993) 61:2322–2325.
   PubMed Web of Science ®Google Scholar
• SHAW PJ, INCE PG, FALKOUS G, MANTLE D: Oxidativedamage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol. (1995) 38:691–695.
   PubMed Web of Science ®Google Scholar
• ABE K, PAN L, WATANABE M, KATO T, ITOYAMA Y: In-duction of tyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci. Lett. (1995) 199:152–154.
   PubMed Web of Science ®Google Scholar
• LIU D, YANG RM YAN X, MCADOO DJ: Hydroxyl radicals generated in vivo kill neurons in the rat spinal cord: electrophysiological, histological and neurochemical results. J. Neurochem. (1994) 62:37–44.
   PubMed Web of Science ®Google Scholar
• GURNEY ME, PU H, CHIU AY: Motor neuron degenera-tion in mice that express a human CuZn superoxide dismutase mutation. Science (1994) 264:1772–1775.
   PubMed Web of Science ®Google Scholar
• LIU R, ALTHAUS JS, ELLERBROCK BR, BECKER DA, GUR-NEY ME: Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lat-eral sclerosis. Ann. Neurol. (1998) 44:763–770.
   PubMed Web of Science ®Google Scholar
• GURNEY ME, CUTTING FB, ZHAI P et al.: Benefit of vita-min E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. (1996) 39:147–157.
   PubMed Web of Science ®Google Scholar
• TROTTI D, DANBOLT NC, VOLTERRA A: Glutamate trans-porters are oxidant-vulnerable: a molecular link be-tween oxidative and excitotoxic neurodegeneration? Trends Pharmacol ScL (1998) 19:328–334.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JI, APPEL SH: IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclero-sis. Arch. Neurol. (1990) 47:210–211.
   Google Scholar
• APPEL SH, ENGELHARDT JI, GARCIA J et al.: Immuno-globulin from animal models of motor neuron disease and human ALS passively transfer physiological ab-normalities of the neuromuscular junction. Proc. Natl. Acad. ScL USA (1991) 88:647–651.
   PubMed Web of Science ®Google Scholar
• UCHITEL OD, SCORNIK F, PROTTI DA et al.: Long-termneuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immuno-globulins. Neurology (1992) 42:2175–80.
   PubMed Web of Science ®Google Scholar
• SMITH RG, HAMILTON S, HOFFMAN F et al.: Serum anti-bodies to skeletal muscle-derived L-type calcium chan-nels in patients with amyotrophic lateral sclerosis. New Engl. J. Med. (1992) 327:1721–1728.
   PubMed Web of Science ®Google Scholar
• SMITH RG, ALEXIANU ME, CRAWFORD G et al.: Cytotox-icily of immunoglobulins from amyotrophic lateral sclerosis. Proc. Natl. Acad. ScL USA (1994) 91:3393–3397.
   PubMed Web of Science ®Google Scholar
• GRIFFIN J, CLARK I, PARHAD D, WATSON D, HOFFMAN P: The neuronal cytoskeleton in disorders of the motor neuron. Adv. Neurol. (1991) 56:103–113.
   PubMedGoogle Scholar
• COTE F, COLLARD J-F, JULIEN JP: Progressive neuropa-thy in transgenic mice expressing the human neuro-filament heavy chain: a mouse model of amyotrophic lateral sclerosis. Cell (1993) 73:35–46.
   PubMed Web of Science ®Google Scholar
• XU Z, CORK LC, GRIFFIN JW, CLEVELAND DW: Increasedexpression of neurofilament subunit NF-L produces morphological alterations that resemble the pathol-ogy of human motor neuron disease. Cell (1993) 73:23–33.
   PubMed Web of Science ®Google Scholar
• HUGON J, VALLAT JM: Abnormal distribution of phos-phorylated neurofilaments in neuronal degeneration induced by kainic acid. NeuroscL Lett. (1990) 119:45–48.
   PubMed Web of Science ®Google Scholar
• CARRIEDO SG, YIN H, WEISS JH: Motor neurons are se-lectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. NeuroscL (1996) 16:4069–4079.
   PubMed Web of Science ®Google Scholar
• WILLIAMS TL, DAY NC, INCE PG, KAMBOJ RK, SHAW PJ:Calcium-permeable alpha-amino-3-hydroxy-5-methy1-4-isoxazole propionic acid receptors: a mo-lecular determinant of selective vulnerability in amyo-trophic lateral sclerosis. Ann. Neurol. (1997) 42:200–207.
   PubMed Web of Science ®Google Scholar
• WALDVOGEL HJ, FAULL RLM, WILLIAMS MN, DRAGU-NOW M: Differential sensitivity of calbindin and par-valbumin immunoreactive cells in the striatum to excitotoxins. Brain Res. (1991) 546:329–335.
   PubMed Web of Science ®Google Scholar
• HUGON J, HUGON F, ESCLAIRE F, LESORT M, DIOP AG:The presence of calbindin in rat cortical neurons pro-tects in vitro from oxidative stress. Brain Res. (1996) 707:288–292.
   PubMed Web of Science ®Google Scholar
• MARTIN D, THOMPSON MA, NADLER JV: The neuropro-tective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CAL Eur. J. Pharmacol. (1993) 250:473–476.
   Google Scholar
• WAHL F, ALLIX M, PLOTKINEM, BOULU RG: Effect of rilu-zole on focal cerebral ischemia in rats. Eur. J. Pharma-col. (1993) 230:209–214.
   PubMed Web of Science ®Google Scholar
• PRATT J, RATAUD J, BARDOT F et al.: Neuroprotective ac-
   Google Scholar
• tions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci. Lett. (1992) 140: 225–230.
   Google Scholar
• BOIREAU AM, DUBEDAT P, BORDIER F et al.: Riluzole and experimental Parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. NeuroReport (1994) 5:2657–2660.
   PubMed Web of Science ®Google Scholar
• BENOIT E, ESCANDE D: Riluzole specifically blocks in-activated Na channels in myelinated nerve fiber. Pflugers Arch. Eur.J. Pharmacol. (1991) 419:603–609.
   PubMed Web of Science ®Google Scholar
• HEBERT T, DRAPEAU P, PRADIER L, DUNN RJ: Block of the rat brain HA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol. Pharmacol. (1994) 45:1055–1060.
   PubMed Web of Science ®Google Scholar
• DEBONO M-W, LE GUERN J, CANTON T, DOBLE A, PRADIER L: Inhibition by riluzole of electrophysiologi-cal responses mediated by rat kainate and NMDA re-ceptors expressed in Xenopus oocytes. Eur. J. Pharmacol. (1993) 235:283–289.
   PubMed Web of Science ®Google Scholar
• MALGOURIS C, DANIEL M, DOBLE A: Neuroprotective ef-fects of riluzole on N-methyl-D-aspartate or verstridine-induced neurotoxicity in rat hippocampal slices. Neurosci. Lett. (1994) 177:95–99.
   PubMed Web of Science ®Google Scholar
• BENSIMON G, LACOMBLEZ L, MEININGER V: A con-trolled trial of riluzole in amyotrophic lateral sclero-sis. New Engl. J. Med. (1994) 330:585–591.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH PN, GUILLET P, MEININGER V: Dose-ranging study of riluzole in amyo-trophic lateral sclerosis. Lancet (1996) 347:1425–1431.
   PubMed Web of Science ®Google Scholar
• TAYLOR CP, GEE NS, SU TZ et al.: A summary of mecha-nistic hypotheses of gabapentin pharmacology. Epi-lepsy Res. (1998) 29:233–249.
   PubMed Web of Science ®Google Scholar
• WELTY DF, SCHIELKE GP, ROTHSTEIN JD: Potential treatment of amyotrophic lateral sclerosis with gabap-entin: a hypothesis. Ann. Pharmacother. (1995) 29:1164–1167.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MOORE D, YOUNG LA et al.: Placebo-controlled trial of gabapentin in patients with amyo-trophic lateral sclerosis. Neurology (1996) 47:1383–1388.
   PubMed Web of Science ®Google Scholar
• PLAITAKIS A, SMITH J, MANDELI J, YAHR MD: Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet (1988) 1:1015–1018.
   PubMed Web of Science ®Google Scholar
• TANDAN R, BROMBERG MB, FORSHEW D et al.: A con-trolled trial of amino acid therapy in amyotrophic lat-eral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology (1996) 47:1220–1226.
   Google Scholar
• GREDAL 0, WERDELIN L, BAK S et al.: A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol. Scand (1997) 96:8–13.
   Google Scholar
• SNIDER WD, JOHNSON EM: Neurotrophic molecules. Ann. Neurol (1989) 26:489–506.
   PubMed Web of Science ®Google Scholar
• THOENEN H: The changing scene of neurotrophic fac-tors. Trends Neuro. ScL (1991) 14:165–170.
   PubMed Web of Science ®Google Scholar
• ELLIOTT JL, SNIDER WD: Motor neuron growth factors. Neurology (1996) 47\(Suppl. 2):S47–S53.
   Google Scholar
• YUEN EC, MOBLEY WC: Therapeutic potential of neuro-trophic factors for neurological disorders. Ann. Neurol. (1996) 40:346–354.
   PubMed Web of Science ®Google Scholar
• CONNOR B, DRAGUNOW M: The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Rev. (1998) 27:1–39.
   PubMed Web of Science ®Google Scholar
• SKAPER SD, WALSH FS: Neurotrophic molecules: strate-gies for designing effective therapeutic molecules in neurodegeneration. Mol. Cell Neurosci. (1998) 12:179–193.
   PubMed Web of Science ®Google Scholar
• SENDTNER M, HOLTMANN B, HUGHES RA: The response of motoneurons to neurotrophins. Neurochem. Res. (1996) 21:831–841.
   PubMed Web of Science ®Google Scholar
• SAGOT Y, VEJSADA R, KATO AC: Clinical and molecular aspects of motoneurone diseases: animal models, neu-rotrophic factors and Bc1-2 oncoprotein. Trends Phar-macol. Sci. (1997) 18:330–337.
   PubMed Web of Science ®Google Scholar
• LOWE WL: Insulin-like growth factors. Sci. Am. Sci. Med. (Mar/Apr 1996):62–71.
   Google Scholar
• LEWIS ME, VAUGHT JL, NEFF NT et al.: The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders. Ann. New York Acad. Sci. (1993) 692:201–208.
   PubMed Web of Science ®Google Scholar
• NEFF NT, PREVETTE D, HOUENOU LJ et al.: Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J. Neurobiol (1993) 24:1558–1566.
   Google Scholar
• CARONI P: Activity-sensitive signals by muscle-derived IGEs in the developing and regenerating neuromuscu-lar system. Ann. N Y Acad. Sci. (1993) 692:209–222.
   PubMed Web of Science ®Google Scholar
• McMANAMAN J, OPPENHEIM RW, PREVETTE D, MARCHETTI D: Rescue of motoneurons from cell death by purified skeletal muscle polypeptide: effects of the ChAT development factor, CDF. Neuron (1990) 4:891–898.
   PubMed Web of Science ®Google Scholar
• CARONI P, GRANDES P: Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. Cell Biol. (1990) 110:1307–1317.
   PubMed Web of Science ®Google Scholar
• HANTAI D, ALAABOUNE M, LAGORD C et al: Beneficial effect of insulin-like growth factor-I on wobbler mouse motoneuron disease. J. Neurol. Sci. (1995) 129(Suppl.):130–139.
   Google Scholar
• LAI EC, FELICE KJ, FESTOFF FW et al: Effect of recombi-nant human insulin-like growth factor-I on progres-sion of ALS. Neurology (1997) 49:1621–1630.
   PubMed Web of Science ®Google Scholar
• HAVERKAMP LJ, APPEL V, APPEL SH: Natural history of amyotrophic lateral sclerosis in a database popula-tion: validation of a scoring system and a model for survival prediction. Brain (1995) 118:707–719.
   PubMed Web of Science ®Google Scholar
• BORASIO GD, ROBBERECHT W, LEIGH PN et al.: A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology (1998) 51:583–586.
   PubMed Web of Science ®Google Scholar
• LEIGH N: The treatment of ALS with recombinant hu-man insulin-like growth factor I (rhIGF-0: pooledanalysis of two clinical trials. Neurology (1997) 48\(Suppl. 2):A217–A218.
   Google Scholar
• LINDSAY RM: Brain-derived neurotrophic factor: an NGF-related neurotrophin. In: Neurotrophic Factors. Loughlin SE, Fallon JH (Eds.), Academic Press, New York, USA (1993):257–284.
   Google Scholar
• JONES KR, FARINAS I, BACKUS C, REICHARDT LF: Tar-geted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell (1994) 76:989–999.
   PubMed Web of Science ®Google Scholar
• KLEIN R, SMEYNE RJ, WURST W et al.: Targeted disrup-tion of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell (1993) 75:113–122.
   PubMed Web of Science ®Google Scholar
• KOLIATSOS VE, CLATTERBUCK RE, WINSLOW JW et al: Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo. Neuron (1993) 10:359–367.
   PubMed Web of Science ®Google Scholar
• IKEDA K, KLINKOSZ B, GREENE T et al.: Effects of brain-derived neurotrophic factor on motor dysfunction in Wobbler mouse motor neuron disease. Ann. Neurol. (1995) 37:505–511.
   PubMed Web of Science ®Google Scholar
• BRADLEY WG: A Phase I/II study of recombinant hu-man brain-derived neurotrophic factor in patients with amyotrophic lateral sclerosis. Ann. Neurol. (1995) 38:971.
   Web of Science ®Google Scholar
• OCHS, PENN RD, GIESS R et al: A trial of recombinant methionyl human brain-derived neurotrophic factor (BDNF) given by intrathecal (IT) infusion to patients with amyotrophic lateral sclerosis (ALS). Neurology (1998) 50\(Suppl. 4):A246.
   Google Scholar
• SENDTNER M, CARROLL P, HOLTMANN B et al: Ciliary neurotrophic factor. J. Neurobiol. (1994) 25:1436–1453.
   PubMedGoogle Scholar
• OPPENHEIM RW, PREVETTE D, YIN QW et al.: Control of embryonic motoneuron survival in vivo by ciliary neu-rotrophic factor. Science (1991) 251:1616–1618.
   PubMed Web of Science ®Google Scholar
• SENDTNER M, KREUTZBERG GW, THOENEN H: Ciliary neurotrophic factor prevents the degeneration of mo-tor neurons after axotomy. Nature (1990) 345:440–441.
   PubMed Web of Science ®Google Scholar
• GURNEY ME, YAMAMOTO H, KWON Y: Induction of mo-tor neuron sprouting in vivo by ciliary neurotrophic factor and basic fibroblast growth factor. J. Neurosci. (1992) 12:3241–3247.
   PubMed Web of Science ®Google Scholar
• MITSUMOTO H, IKEDA K, HOLMLUND T etal.: The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. (1994) 36:142–148.
   Google Scholar
• ALS CNTF TREATMENT STUDY GROUP: A double-blind placebo-controlled clinical trial of subcutaneous re-combinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurol (1996) 47:1244–1249.
   Google Scholar
• MILLER RG, PETAJAN JH, BRYAN WW et al.: A placebo-controlled trial of recombinant human ciliary neuro-trophic (rhCNTF) factor in amyotrophic lateral sclero-sis. Ann. Neurol (1996) 39:256–260.
   PubMed Web of Science ®Google Scholar
• AEBISCHER P, SCHLUEP M, DEGLON N et al.: Intrathecal delivery of CNTF using encapsulated genetically modi-fied xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med. (1996) 2:696–699.
   PubMed Web of Science ®Google Scholar
• JING S, WEN D, YU Y et al.: GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-a, a novel receptor for GDNF. Cell (1996) 85:1113–1124.
   PubMed Web of Science ®Google Scholar
• SANCHEZ MP, SILOS-SANTIAGO I, FRISEN J et al.: Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature (1996) 382:70–73.
   PubMed Web of Science ®Google Scholar
• MOORE MW, KLEIN RD, FARINAS I et al.: Renal and neu-ronal abnormalities in mice lacking GDNF. Nature (1996) 382:76–79.
   PubMed Web of Science ®Google Scholar
• LI L, WU W, LIN LF, LEI M, OPPENHEIM RW, HOUENOU LJ: Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neuro-trophic factor. Proc. Natl. Acad. Sci. USA (1995) 92:9771–9775.
   PubMed Web of Science ®Google Scholar
• KLINKOSZ B, PIORO EP, YAN Q, MITSUMOTO H. Glial cell line-derived neurotrophic factor reduces motor dysfunction in wobbler mice. Ann. Neurology (1996) 40:540.
   Google Scholar
• PRADINES A, MAGAZIN M, SCHILTZ P, LE FUR G, CAPUTD, FERRARA P: Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J. Neurochem. (1995) 64:1954–1959.
   PubMed Web of Science ®Google Scholar
• FOURNIER J, STEINBERG R, GAUTHIER T et al.: Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and pri-mates. Neuroscience (1993) 55:629–641.
   PubMed Web of Science ®Google Scholar
• LOUWERSE ES, WEVERLING GJ, BOSSUYT PMM et al.: Randomized, double-blind, controlled trial of acetyl-cysteine in amyotrophic lateral sclerosis. Arch. Neurol (1995) 52:559–564.
   PubMed Web of Science ®Google Scholar
• LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol (1998) 55:93–96.
   PubMed Web of Science ®Google Scholar
• BORASIO GD, HORSTMAN S, ANNESER JMH, NEFF NT, GLICKMAN MA: CEP-1347/KT7515, a junk pathway in-hibitor, supports the in vitro survival of chick embry-onic neurones. NeuroReport (1998) 9:1435–1439.
   PubMed Web of Science ®Google Scholar
• KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuro-protective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med. (1999) 5:347–350.
   PubMed Web of Science ®Google Scholar
• BORASIO GD: Amyotrophic lateral sclerosis: lessons in trial design from recent trials. J. Neurol Sci. (1997) 152 (Suppl. 1):S23–S28.
   Google Scholar